

# 1 ***APOE-ε4* and *BIN1* increase risk of Alzheimer's disease pathology but not specifically** 2 **of Lewy body pathology**

3 Seth Talyansky<sup>1†</sup>, Yann Le Guen<sup>1,2\*†</sup>, Nandita Kasireddy<sup>1</sup>, Michael E. Belloy<sup>1</sup>, and Michael D. Greicius<sup>1</sup>

4 <sup>1</sup>Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA

5 <sup>2</sup>Institut du Cerveau – Paris Brain Institute – ICM, Paris, France

6 <sup>†</sup>Equal contributor

7 <sup>\*</sup>Correspondence:

8 Department of Neurology and Neurological Sciences – Greicius lab

9 Stanford University

10 290 Jane Stanford Way, E265, CA 94305-5090

11 Tel: 650 666 2696

12 Email: [yleguen@stanford.edu](mailto:yleguen@stanford.edu)

## 13 **Abstract**

14 Lewy body (LB) pathology commonly occurs in individuals with Alzheimer's disease (AD) pathology.  
15 However, it remains unclear which genetic risk factors underlie AD pathology, LB pathology, or AD-  
16 LB co-pathology. Notably, whether *APOE-ε4* affects risk of LB pathology independently from AD  
17 pathology is controversial. We adapted criteria from the literature to classify 4,985 subjects from the  
18 National Alzheimer's Coordinating Center (NACC) and the Rush University Medical Center as AD-LB  
19 co-pathology (AD+LB<sup>+</sup>), sole AD pathology (AD+LB<sup>-</sup>), sole LB pathology (AD-LB<sup>+</sup>), or no pathology  
20 (AD-LB<sup>-</sup>). We performed a meta-analysis of a genome-wide association study (GWAS) per  
21 subpopulation (NACC/Rush) for each disease phenotype compared to the control group (AD-LB<sup>-</sup>),  
22 and compared the AD+LB<sup>+</sup> to AD+LB<sup>-</sup> groups. *APOE-ε4* was significantly associated with risk of AD+LB<sup>-</sup>  
23 and AD+LB<sup>+</sup> compared to AD-LB<sup>-</sup>. However, *APOE-ε4* was not associated with risk of AD-LB<sup>+</sup>  
24 compared to AD-LB<sup>-</sup> or risk of AD+LB<sup>+</sup> compared to AD+LB<sup>-</sup>. Associations at the *BIN1* locus exhibited  
25 qualitatively similar results. These results suggest that *APOE-ε4* is a risk factor for AD pathology, but  
26 not for LB pathology when decoupled from AD pathology. The same holds for *BIN1* risk variants.  
27 These findings, in the largest AD-LB neuropathology GWAS to date, distinguish the genetic risk  
28 factors for sole and dual AD-LB pathology phenotypes. Our GWAS meta-analysis summary statistics,  
29 derived from phenotypes based on postmortem pathologic evaluation, may provide more accurate  
30 disease-specific polygenic risk scores compared to GWAS based on clinical diagnoses, which are  
31 likely confounded by undetected dual pathology and clinical misdiagnoses of dementia type.

## 32 **Introduction**

33 Alzheimer's disease (AD) pathology has been the focus of many studies, but Lewy body (LB)  
34 pathology has received less attention. In individuals with AD, LB pathology frequently co-occurs with  
35 AD pathology, while LB pathology alone or accompanied by limited AD pathology is characteristic of  
36 Parkinson's disease (PD) and LB dementia [30, 53, 49, 54]. Genetic variants associated with AD  
37 pathology, LB pathology, and/or AD-LB co-pathology remain to be distinguished. Characterizing each  
38 set of risk factors and any potential overlap will help clarify the etiology of AD and LB pathology. AD  
39 pathology is found in 19–67% of older individuals at autopsy, depending on the population, the  
40 individual's age, and the diagnostic criteria used [44]. LB pathology is observed in 6–39% of older  
41 individuals, but in 60% of individuals with AD pathology [44, 30, 34]. Positive classification for LB  
42 pathology requires, at a minimum, the presence of  $\alpha$ -synuclein-bearing Lewy bodies in the brainstem,  
43 with further extension of LB pathology into the limbic system associated with the clinical diagnosis  
44 of dementia [38]. Positive classification for AD pathology requires the presence of tau neurofibrillary  
45 tangles (NFTs) in the limbic system along with amyloid- $\beta$  core neuritic plaques in the cortex [8, 39].  
46 Lewy bodies and NFTs spread to the cortex late in the progression of either pathology [38, 8]. Braak  
47 staging is the primary scheme used to classify NFT progression, while the Consortium to Establish a  
48 Registry for Alzheimer's Disease (CERAD) scoring is the primary scheme used to classify neuritic  
49 plaque density. AD has traditionally been defined pathologically as Braak stage IV or higher, and at  
50 least moderate CERAD [17], although some studies have used less stringent criteria (Braak stage III  
51 or higher, and at least sparse CERAD) [28]. Thal phasing of amyloid- $\beta$  non-neuritic plaques [51],  
52 based on another staging devised by Braak [9], has more recently been used as a third essential  
53 metric to classify AD [11]. Of the five Thal phases, only the last two, in which plaques are present in  
54 the brainstem and cerebellum, are specific to dementia patients [17].

55 Clinical diagnoses of AD and LB dementia are challenging and error-prone in comparison to the gold  
56 standard of a pathologic diagnosis [19]. However, most study participants have only been clinically  
57 diagnosed due to the scarcity of postmortem pathologically confirmed data. In a study of 919  
58 autopsied individuals comparing clinical diagnosis of AD to pathological diagnosis, the diagnosis of  
59 clinically probable AD had an 83% positive predictive value (PPV) for pathological criteria of Braak  
60 state III or higher and moderate/high CERAD [1]. This study was conducted before AD biomarkers  
61 like spinal fluid amyloid and tau levels, or amyloid and tau PET scans, were more commonly used, so  
62 the PPV of the clinical diagnosis is now likely higher than 83%; however, it remains imperfect. The  
63 PPV for a clinical diagnosis of probable LB dementia against the pathologic diagnosis is also around  
64 80% [21, 50, 45]. In general, it has been difficult to clinically distinguish between AD without Lewy

65 bodies, AD with Lewy bodies, and LB dementia [25]. Additionally, individuals who may have  
66 advanced pathology, but mild symptoms are frequently misdiagnosed clinically or missing from  
67 clinical datasets altogether because they do not seek medical attention.

68 Motor function and neuropsychiatric and cognitive symptoms have been suggested as diagnostic  
69 clues of AD pathology, LB pathology, or co-pathology [14, 48]. Moreover, developing AD pathology  
70 biomarkers such as assays of amyloid- $\beta$ , tau, and phosphorylated tau levels in the cerebrospinal fluid  
71 or blood plasma has been valuable in closing the gap between diagnosis during life and pathologic  
72 AD diagnosis [6, 32]. LB pathology biomarkers, including promising assays of  $\alpha$ -synuclein aggregates  
73 in the cerebrospinal fluid, are similarly improving the diagnosis of LB dementia [47, 43, 36]. Still,  
74 because LB biomarkers have been developed more recently, most existing genetic datasets consist of  
75 only clinically diagnosed subjects. Ultimately, as a histological and molecular endophenotype,  
76 pathologic diagnosis offers the most reliable insights into the genetic drivers of disease.

77 Previous research has produced contrasting and somewhat ambiguous findings on the genetic risk  
78 loci for AD and LB pathology. This could be because most studies include only clinically assessed  
79 subjects or have relatively few pathologically assessed subjects. Importantly, most prior studies on  
80 AD and LB pathology, even with pathologic confirmation, do not stratify subjects into distinct groups  
81 for sole AD pathology (AD-LB<sup>-</sup>), LB pathology (AD-LB<sup>+</sup>), co-pathology (AD+LB<sup>+</sup>), and neither  
82 pathology (AD-LB<sup>-</sup>), making the results difficult to accurately interpret. It is well known that the  $\epsilon 4$   
83 allele of the *Apolipoprotein E* (*APOE*) gene is the strongest common genetic risk factor for AD [4, 31].  
84 However, various studies have reported that *APOE*- $\epsilon 4$  is also associated with increased risk of sole  
85 LB pathology (AD-LB<sup>+</sup>) [52, 18], LB dementia [5, 2, 24, 48, 13], or increased risk of AD-LB co-  
86 pathology (AD+LB<sup>+</sup>) in AD individuals [14]. Walker and Richardson (2023) found that *APOE*- $\epsilon 4$  was  
87 associated with AD, LB, or limbic-predominant age-related TDP-43 encephalopathy pathology as well  
88 as with the presence of multiple of these pathologies [54]. This suggests that *APOE*- $\epsilon 4$  could be  
89 associated with AD-LB<sup>+</sup> pathology.

90 How *APOE*- $\epsilon 4$  affects the severity of LB pathology has also been investigated. Studies reported that  
91  $\alpha$ -synuclein pathology mouse models expressing *APOE*- $\epsilon 4$  develop more extensive inclusions [22,  
92 16]. In humans, LB pathology was found to be more severe among *APOE*- $\epsilon 4$  carriers independent of  
93 AD pathology severity [23], as well as among *APOE*- $\epsilon 4$ -carrying AD-LB<sup>+</sup> subjects relative to non-  
94 carriers [18, 22, 57]. However, when Kaivola *et al.* (2022) categorized pathologically confirmed cases  
95 from the cohort in [13] by not only LB but also AD pathology status, *APOE*- $\epsilon 4$  was not associated with  
96 risk of AD-LB<sup>+</sup> pathology [28]. Robinson *et al.* (2018) found that *APOE*- $\epsilon 4$  was associated with cortical  
97 LB co-pathology (cortical LB pathology accompanied by an amyloidopathy, tauopathy, or TDP-43

98 proteinopathy) compared to sole LB pathology; however, *APOE-ε4* was not associated with AD-LB  
99 co-pathology compared to sole AD pathology [46]. Furthermore, Dickson *et al.* (2018) found that  
100 *APOE-ε4* was not associated with more severe LB pathology in individuals with moderate or high AD  
101 pathology [18]. It, therefore, remains unclear whether *APOE-ε4* in fact increases risk of AD-LB+  
102 pathology.

103 Importantly, beyond *APOE-ε4*, there may be other pathology-specific genetic risk loci yet to be  
104 identified. Along this line, it is relevant to note that removing individuals that are not pathologically  
105 evaluated from study cohorts has been shown to reduce noise in genome-wide association studies  
106 (GWAS) and to improve polygenic risk score analyses of AD [15, 20, 19]. These observations  
107 emphasize the need for novel GWAS of AD/LB pathology to better characterize the genetic  
108 architecture of these complex dementias.

109 To this end, we assembled a preliminary cohort of 5,254 individuals with genetic data and autopsy-  
110 confirmed AD and LB pathology status, the largest such cohort to date. We adapted criteria from the  
111 literature to categorize these individuals as AD+LB+, AD+LB-, AD-LB+, or AD-LB-, yielding 1,072  
112 AD+LB+, 2,492 AD+LB-, 158 AD-LB+, and 1,263 AD-LB- individuals in our study cohort (total N =  
113 4,985). We compared each disease category to controls by performing separate GWAS meta-analyses.  
114 We also compared AD+LB+ pathology to AD+LB- pathology in another analysis.

## 115 **Materials and methods**

### 116 **Study cohort**

117 We analyzed data from individuals from the National Alzheimer's Coordinating Center (NACC) and  
118 Rush University Medical Center databases who were evaluated postmortem for both AD and LB  
119 pathology. We excluded NACC individuals who were classified as having Lewy bodies in the olfactory  
120 bulb or in an "unspecified" region (individuals for whom the NACCLEWY parameter was equal to 4).  
121 We also excluded individuals missing sex or age-at-death information. In total, our preliminary  
122 cohort comprised 5,254 individuals before classification according to AD and LB pathology status.  
123 This cohort was distinct from that analyzed in [13], the largest genetic study of LB dementia (which  
124 included subjects without pathology verification), and [28], the largest previous genetic study of  
125 subjects categorized by both AD and LB pathology status.

### 126 **Pathological criteria**

127 We classified individuals as having both AD and LB pathology (AD+LB<sup>+</sup>), AD pathology only (AD+LB<sup>-</sup>),  
128 LB pathology only (AD-LB<sup>+</sup>), or neither pathology (AD-LB<sup>-</sup>) (**Fig. 1**). Individuals who could not be  
129 classified using our criteria were excluded (**Fig. 1c**). In sensitivity analyses, we applied the pathology  
130 criteria from [52] and [28] to our preliminary cohort (**Fig 1. a-b**). Criteria were set as follows for LB  
131 pathology.

- 132     ▪ LB<sup>+</sup> pathology were individuals with Lewy bodies spread to the limbic system or cortex, as  
133         in [28] and [52].
- 134     ▪ LB<sup>-</sup> pathology were individuals with no Lewy bodies or Lewy bodies limited to the brainstem,  
135         as in [28], but not in [52], which excluded individuals with brainstem-limited Lewy bodies.
- 136     ▪ Some gray zones, representing rare subcategories with unclassified individuals, are defined  
137         based on Braak stage and CERAD score below.

138 Criteria for AD pathology were less straightforward because of borderline subcategories and possible  
139 confounding with other pathologies. In agreement with [28] and [52] (**Fig. 1**),

- 140     ▪ AD<sup>+</sup> pathology included individuals with Braak stage IV or higher and CERAD score moderate  
141         or frequent.
- 142     ▪ AD<sup>-</sup> pathology included individuals with Braak stage II or lower, or Braak stage III/IV and  
143         CERAD score absent.

144 Other subcategories were largely classified differently between [28] and [52], and we settled on the  
145 following criteria. First, we defined three gray zones of unclassified individuals corresponding to rare  
146 pathologic profiles (N = 269 total).

- 147       ▪ Individuals who had Braak stage V/VI and CERAD score absent, regardless of LB category,  
148       were not classified for the reason of likely having a rare tauopathy distinct from AD [41].  
149       ▪ Similarly, individuals with absent or brainstem Lewy bodies (LB-) who had Braak stage V/VI  
150       and CERAD score sparse were not classified.  
151       ▪ Braak stage III and CERAD score frequent in LB- individuals were insufficient for  
152       classification as AD+, but too high for a confident classification as AD-. Ultimately, our goal  
153       was to obtain a clean control (AD-LB-) group.

154 Second, certain borderline subcategories were classified differently (AD+ or AD-) depending on LB  
155 category.

- 156       ▪ Individuals with absent or brainstem Lewy bodies (LB-) were AD- for Braak stage III and  
157       CERAD score sparse or moderate; or Braak stage IV and CERAD score sparse.  
158       ▪ Individuals with limbic or cortical Lewy bodies (LB+) were AD+ for Braak stage III or higher  
159       and CERAD score sparse; or Braak stage III and CERAD score moderate or frequent.

160 Using our criteria (**Fig. 1c**), we categorized our preliminary cohort into 1,072 AD+LB+, 2,495 AD+LB-,  
161 158 AD-LB+, and 1,263 AD-LB- individuals; these 4,985 individuals formed our study cohort (**Table**  
162 **1**). Overall, the set of four phenotypes was better represented in our study than in previous studies  
163 (**Suppl. Table 1**), which stratified subjects less completely or had fewer individuals in total (Tsuang  
164 *et al.*).

### 165 **Genome-wide analysis**

166 We performed a meta-analysis of separate GWAS in the NACC and Rush subsets of our cohort for each  
167 of AD+LB+, AD+LB-, and AD-LB+ pathology compared to AD-LB- pathology, as well as for AD+LB+ versus  
168 AD+LB- pathology. We used PLINK 2.0 for logistic regression and included sex, age-at-death, and the  
169 top ten principal components accounting for genetic ancestry as covariates [11]. We removed  
170 duplicates and first-degree relatives within and between genomic datasets using KING [37]. In each  
171 pair of relatives, the relative with younger age at death was preferentially kept or the oldest control  
172 in the absence of pathology cases. We filtered out genetic variants that had a minor allele frequency  
173 below 0.01, departed from Hardy-Weinberg equilibrium with a significance below  $P < 10^{-5}$ , or had a  
174 missingness rate above 20%. We imputed data on the TOPMed reference panel as described in [33]  
175 and considered variants with  $R^2 > 0.8$ . We meta-analyzed the separate NACC and Rush GWAS using  
176 the inverse variance weighted method in METAL [55]. Manhattan plots from summary statistics were  
177 produced using the R package CMplot [56]. The significance threshold was set at  $P < 5 \times 10^{-8}$ , the  
178 standard threshold for genome-wide significance. We estimated the association of *APOE-ε4* with risk  
179 of AD+LB+, AD+LB-, and AD-LB+ pathology relative to AD-LB- pathology, and the association with risk

180 of AD+LB<sup>+</sup> pathology relative to AD+LB<sup>-</sup> pathology, in terms of odds ratio (OR). We also estimated the  
181 association of *APOE*- $\epsilon$ 2. We compared our estimates to those in the literature [52, 28, 13, 2, 10, 14,  
182 18, 46, 48] and when relevant we computed measures of linkage disequilibrium between variants in  
183 European ancestry populations using LDlink [35]. We examined loci besides *APOE* that led to  
184 genome-wide significant signals. We explored lead variant annotation at significant loci using  
185 gnomAD [45]. Finally, we surveyed AD and PD risk loci reported in large clinical case-control GWAS  
186 [3, 12, 40] and report the ones associated with pathology at the nominal significance level ( $P < 0.05$ )  
187 in our study.

## 188 Results

189 We observed that *APOE-ε4* (rs429358) was associated with risk of AD+LB+ pathology versus AD-LB-  
190 pathology (OR = 4.24, 95% CI = 3.52–5.10,  $P = 1.5 \times 10^{-52}$ ) and risk of AD+LB- pathology versus AD-  
191 LB- pathology (OR = 4.22, 95% CI = 3.60–4.96,  $P = 1.4 \times 10^{-69}$ ) (**Fig. 2a–b; Table 4**). We did not  
192 observe an association of *APOE-ε4* with the risk of AD-LB+ pathology versus AD-LB- pathology (OR =  
193 0.93, 95% CI = 0.60–1.43,  $P = 0.73$ ) or risk of AD+LB+ pathology versus AD+LB- pathology (OR = 1.01,  
194 95% CI = 0.90–1.13,  $P = 0.83$ ) (**Fig. 2c–d; Table 4**). Another gene locus that yielded significant  
195 associations was *BIN1*. Like *APOE-ε4*, we observed that rs4663105 on the *BIN1* locus was associated  
196 with risk of AD+LB- pathology compared to AD-LB- pathology (OR = 1.40, 95% CI = 1.26–1.56,  $P = 6.5$   
197  $\times 10^{-10}$ ) and risk of AD+LB+ pathology compared to AD-LB- pathology (OR = 1.53, 95% CI = 1.35–1.75,  
198  $P = 1.4 \times 10^{-10}$ ) (**Fig. 2a–b; Table 5**). rs4663105 was not observed to be associated with risk of AD-  
199 LB+ pathology versus AD-LB- pathology (OR = 1.10, 95% CI = 0.85–1.41,  $P = 0.48$ ) or risk of AD+LB+  
200 pathology versus AD+LB- pathology (OR = 1.13, 95% CI = 1.02–1.25,  $P = 0.019$ ) at the genome-wide  
201 significance level (**Fig. 2c–d; Table 5**). When using pathological criteria from Tsuang *et al.* (2013)  
202 (**Fig. 1a**), effect estimates for *APOE-ε4* differed considerably from those reported in the original  
203 study, particularly so for the effect on AD-LB+ vs. AD-LB- (**Table 4**). On the contrary, there was fair  
204 agreement when using pathological criteria from Kaivola *et al.* (2022) (**Fig. 1b; Table 4**). *APOE-ε2*  
205 showed similar results to *APOE-ε4*, except with the opposite direction of effect in the GWAS where  
206 *APOE-ε4* exhibited an association (**Suppl. Table 3**). Overall, we observed an enrichment among the  
207 79 variants listed in the clinical AD GWAS (Bellenguez *et al.* (2022)) and tested in our analyses; we  
208 observed an enrichment of nominally significant associations with concordant direction of effect:  
209 20.3% variants (16/79) in the AD+LB- vs. AD-LB- contrast and 24.1% (19/79) in the AD+LB+ vs. AD-  
210 LB- (with the chance level being at 2.5%). In contrast, we did not observe a significant enrichment  
211 for the 76 variants identified in PD clinical GWAS Chang *et al.* (2017) and Nalls *et al.* (2019): 2.6%  
212 (2/76) in the AD+LB+ vs. AD-LB- contrast, 3.9% (3/76) in the AD-LB+ vs. AD-LB- contrast, and 2.6%  
213 (2/76) in the AD+LB+ vs. AD+LB- contrast. Among known AD risk loci besides *BIN1* and *APOE* reported  
214 by Bellenguez *et al.* (2022), *ADAM17* (rs72777026), *COX7C* (rs62374257), *HLA* (rs6605556), *TREM2*  
215 (rs143332484), *HS3ST5* (rs785129), *SEC61G* (rs76928645), *CLU* (rs11787077), *ECHDC3*  
216 (rs7912495), *TPCN1* (rs6489896), *FERMT2* (rs17125924), *DOC2A* (rs1140239), *PRDM7*  
217 (rs56407236), *ABI3* (rs616338), *ABCA7* (rs12151021), and *SIGLEC11* (rs9304690) were concordant  
218 and nominally associated with AD+LB+ versus AD-LB-; and *CR1* (rs679515), *ADAM17* (rs72777026),  
219 *INPP5D* (rs10933431), *CLNK/HS3ST1* (rs6846529), *ANKH* (rs112403360), *COX7C* (rs62374257),  
220 *HLA* (rs6605556), *TREM2* (rs143332484), *ZCWPW1/NYAP1* (rs7384878), *PTK2B* (rs73223431),



221 *CLU* (rs11787077), *ECHDC3* (rs7912495), *PICALM* (rs3851179), *SORL1* (rs11218343), *FERMT2*  
222 (rs17125924), *APH1B* (rs117618017), *MAF* (rs450674), and *ABCA7* (rs12151021) were concordant  
223 and nominally associated with AD+LB<sup>-</sup> pathology versus AD-LB<sup>-</sup> (**Table 6; Suppl. Table 5**). Among  
224 known PD risk loci reported by Chang *et al.* (2017) and Nalls *et al.* (2019), *SCN3A* (rs353116) and  
225 *HLA-DRB6/HLA-DQA1* (rs9275326) were concordant and nominally associated with AD+LB<sup>+</sup> versus  
226 AD-LB<sup>-</sup>; *TMEM175/DGKQ* (rs34311866), *FAM200B/CD38* (rs11724635), and *SNCA* (rs356182) were  
227 concordant and nominally associated with AD-LB<sup>+</sup> versus AD-LB<sup>-</sup>; and *GBA* (rs35749011) and  
228 *TMEM175/DGKQ* (rs34311866) were concordant and nominally associated with AD+LB<sup>+</sup> versus  
229 AD+LB<sup>-</sup> (**Table 6; Suppl. Table 5**). Notably, the *TPCN1* locus, reported to be associated with LB  
230 dementia by Kaivola *et al.* (2023), was associated with AD+LB<sup>+</sup> pathology and AD+LB<sup>-</sup> pathology  
231 versus AD-LB<sup>-</sup> pathology below or near the nominal significance level, but not so with AD-LB<sup>+</sup>  
232 pathology versus AD-LB<sup>-</sup> pathology or AD+LB<sup>+</sup> pathology versus AD+LB<sup>-</sup> pathology.

## 233 Discussion

234 Our study emphasizes that *APOE-ε4* is associated with the risk of both AD+LB<sup>-</sup> pathology (OR = 4.22,  
235  $P = 1.4 \times 10^{-69}$ ) and AD+LB<sup>+</sup> co-pathology (OR = 4.24,  $P = 1.5 \times 10^{-52}$ ) compared to AD-LB<sup>-</sup> pathology.  
236 These OR estimates were lower than the estimates in Tsuang *et al.* for *APOE-ε4*-associated risk of  
237 AD+LB<sup>-</sup> pathology (OR = 12.6,  $P = 2.1 \times 10^{-28}$ ) and AD+LB<sup>+</sup> co-pathology (OR = 9.9,  $P = 1.2 \times 10^{-24}$ )  
238 (**Table 4**) [52]. Tsuang *et al.* appear to have overestimated the true effect size of *APOE-ε4* in their  
239 positive pathology subjects, possibly due to the smaller size of their cohort [52] (N = 640 versus N =  
240 4,985 in the current study) (**Table 3**). Our estimate of *APOE-ε4*-associated risk for AD+LB<sup>+</sup> pathology  
241 is in line with the estimate in Kaivola *et al.*, the next largest study of pathologically assessed  
242 individuals (OR = 4.25,  $P = 1.29 \times 10^{-32}$ ) [28]. Our data substantiate that *APOE-ε4* is a driver of AD  
243 pathology. Notably, we estimated a similar effect size of *APOE-ε4* on the risk of AD+LB<sup>-</sup> pathology (OR  
244 = 4.22) and on the risk of AD+LB<sup>+</sup> co-pathology (OR = 4.24) versus AD-LB<sup>-</sup> pathology, suggesting that  
245 *APOE-ε4* does not have a specific effect on the development of LB pathology in individuals with AD  
246 pathology. Consistent with this finding, we did not observe *APOE-ε4* to be associated with the risk of  
247 AD+LB<sup>+</sup> co-pathology compared to sole AD+LB<sup>-</sup> pathology (OR = 1.01,  $P = 0.83$ ).

248 This finding contradicts the results presented by Chung *et al.* (2015), where *APOE-ε4* was found to  
249 be associated with AD+LB<sup>+</sup> co-pathology when compared to sole AD+LB<sup>-</sup> pathology ( $P = 0.03$ ) [14].  
250 However, their AD+LB<sup>+</sup> group was five times smaller than ours (N = 215 versus N = 1,072), and the  
251 AD+LB<sup>-</sup> group was eight times smaller (N = 316 versus N = 2,492). Our result is consistent with the  
252 finding in Robinson *et al.* (2018) that *APOE-ε4* is not associated with the co-occurrence of AD  
253 pathology with other pathologies (OR = 0.71,  $P = 0.64$  for intermediate AD pathology; and OR = 0.93,  
254  $P = 0.83$  for high AD pathology) [46]. Our result is also consistent with the finding in Dickson *et al.*  
255 (2018) that *APOE-ε4* is not associated with higher Lewy body count in individuals with moderate AD  
256 pathology ( $P \geq 0.30$  for all regions) or high AD pathology ( $P \geq 0.069$  for all regions) [18]. Taken  
257 together, *APOE-ε4* appears similarly prevalent in AD pathology cases with or without LB pathology.  
258 Furthermore, we did not find *APOE-ε4* to be associated with risk for sole LB pathology (AD-LB<sup>+</sup>)  
259 pathology (OR = 0.93,  $P = 0.73$ ) compared to no pathology (AD-LB<sup>-</sup>). This is in contradiction with [52]  
260 where *APOE-ε4* was strongly associated with risk for AD-LB<sup>+</sup> pathology (OR = 6.1,  $P = 1.3 \times 10^{-10}$ ).  
261 This discrepancy could be because Tsuang *et al.* used a more stringent definition of AD pathology  
262 (**Fig. 1a**), leaving open the possibility that individuals whom we would have classified as AD+LB<sup>+</sup> with  
263 our criteria were instead classified as AD-LB<sup>+</sup>. Indeed, when we categorized our initial pathologically  
264 evaluated cohort using the exact same criteria as in [52], testing the association of *APOE-ε4* with risk  
265 of AD-LB<sup>+</sup> pathology yielded a modestly higher OR and nominal significance (OR = 1.46,  $P = 5.5 \times$

266  $10^{-3}$ ) (**Table 4**). The main difference between our criteria and those of Tsuang *et al.* is that we lower  
267 the threshold for AD pathology to Braak stage III NFTs plus sparse neuritic plaques in LB<sup>+</sup> individuals,  
268 suggesting that LB pathology commonly occurs in *APOE-ε4* carriers with potential early-stage AD but  
269 not in firmly non-AD *APOE-ε4* carriers. Knowing the breakdown of the *APOE-ε4*-positive subjects in  
270 [52] by Braak stage and CERAD score would establish further support for this interpretation.

271 Dickson *et al.* also found an association of *APOE-ε4* with the risk of diffuse LB pathology and low AD  
272 pathology (OR = 3.46,  $P = 0.001$ ) while classifying individuals with Braak stage III NFTs and Thal  
273 phase 0, 1, or 2 amyloid-β non-neuritic plaques as having low AD pathology [18]. In this AD-LB<sup>+</sup>  
274 group, the median Braak stage was III and the median Thal phase was 1. We would have classified  
275 this subset as AD<sup>+</sup>LB<sup>+</sup>. A Thal phase of 1 tends to correspond to a CERAD score of sparse neuritic  
276 plaques or higher [7]. Therefore, many individuals in this AD-LB<sup>+</sup> group in [18] had a Braak stage of  
277 III and at least sparse neuritic plaques; this subset was likely the source of the elevated frequency of  
278 *APOE-ε4* in the group. We would have classified this subset as AD<sup>+</sup>LB<sup>+</sup> instead. It should be noted that  
279 this AD-LB<sup>+</sup> group in Dickson *et al.* was smaller than ours (N = 54 versus N = 158) and the controls  
280 were not pathologically confirmed. Another cause of the discrepancy between our result that *APOE-*  
281 *ε4* was not associated with the risk of AD-LB<sup>+</sup> pathology and Tsuang *et al.*'s finding that *APOE-ε4*  
282 increased risk for LB pathology may have been that the pathologically confirmed AD-LB<sup>-</sup> group in  
283 [52] was more than four times smaller than ours (N = 269 versus N = 1,263). Remarkably, the  
284 frequency of *APOE-ε4* was 31.9% in the AD-LB<sup>+</sup> group [52], which was far higher than in our AD-LB<sup>+</sup>  
285 group (8.9%). Our result was consistent with the finding in Dickson *et al.* that *APOE-ε4* was not  
286 associated with the risk of the AD-LB<sup>+</sup> phenotype of transitional (limbic) LB pathology and low AD  
287 pathology (OR = 0.73,  $P = 0.31$ ) [18].

288 In a larger study than [52] of pathologically confirmed LB dementia cases and mixed pathologic and  
289 clinical controls, Chia *et al.* found that *APOE-ε4* was associated with risk of LB dementia: OR = 2.45  
290 with  $P = 4.65 \times 10^{-63}$  for rs769449, which is in linkage disequilibrium with *APOE-ε4* with  $R^2 = 0.766$   
291 [13]. However, this could have been because Chia *et al.* did not categorize individuals by AD pathology  
292 status, and many AD<sup>+</sup>LB<sup>+</sup> individuals were inevitably included in the LB<sup>+</sup> case group. When Kaivola *et*  
293 *al.* studied the cohort in Chia *et al.* using more precise pathological categorization, *APOE-ε4* was not  
294 observed to have a significant effect on risk for AD-LB<sup>+</sup> pathology (OR = 0.75,  $P = 0.31$ ) [28].  
295 Associations of *APOE-ε4* with risk of LB pathology (OR = 1.63,  $P = 2.8 \times 10^{-11}$ ) and LB dementia (OR  
296 = 2.71,  $P = 7.1 \times 10^{-35}$ ; OR = 2.40,  $P = 1.05 \times 10^{-48}$ ; and OR = 2.94,  $P = 6.6 \times 10^{-20}$ ) reported in Beecham  
297 *et al.* (2014), Bras *et al.* (2014), Guerreiro *et al.* (2018), and Sabir *et al.* (2019), respectively, could  
298 similarly have been because these studies did not exclude AD<sup>+</sup>LB<sup>+</sup> individuals from their LB<sup>+</sup> case

299 groups [2, 10, 24, 48]. Our finding was also consistent with the result in Robinson *et al.* that *APOE-ε4*  
300 was associated with the co-occurrence of cortical LB pathology with other pathologies, including AD  
301 pathology, versus sole cortical LB pathology (OR = 9.32,  $P = 0.003$ ) [46]. The latter result would imply  
302 that *APOE-ε4* was rarer in the AD-LB<sup>+</sup> individuals in [46] than in LB<sup>+</sup> individuals with advanced LB  
303 pathology. Presumably, because 80% of LB<sup>+</sup> individuals also had AD pathology, the prevalence of  
304 *APOE-ε4* in LB<sup>+</sup> individuals was most likely unrelated to the presence of LB pathology.

305 The balance of evidence thus suggests that *APOE-ε4* does not affect risk for AD-LB<sup>+</sup> pathology when  
306 strictly defined to exclude possible early-stage AD. Subjects with LB pathology and no AD pathology  
307 have been rare, and more are needed to substantiate this conclusion. This concept does not oppose  
308 the observations in Dickson *et al.* and Zhao *et al.* (2020) that *APOE-ε4* was associated with higher LB  
309 counts in AD-LB<sup>+</sup> subjects, as neither analysis compared cases to controls without pathology [18, 57].  
310 Similarly compatible is the observation in Goldberg *et al.* (2020) that *APOE-ε4* was associated with  
311 further propagated Lewy bodies; although Goldberg *et al.* adjusted for AD pathology level, their  
312 analysis did not specifically compare LB<sup>+</sup> to LB<sup>-</sup> subjects [23]. It is conceivable that *APOE-ε4* worsens  
313 LB pathology but does not influence its actual emergence in individuals without AD pathology.

314 Overall, our data suggest *APOE-ε4* is most likely not involved in the emergence of LB pathology in the  
315 absence or presence of AD pathology. This interpretation is further supported by the lack of an effect  
316 of *APOE-ε4* in the largest GWAS of clinically defined PD (OR = 1.02,  $P = 0.49$ ) [40].

317 A second gene locus that yielded significant associations was *BIN1*. As for *APOE-ε4*, the *BIN1* lead  
318 variant was associated with the risk of sole AD (AD<sup>+</sup>LB<sup>-</sup>) and AD<sup>+</sup>LB<sup>+</sup> co-pathology, but not sole LB  
319 (AD-LB<sup>+</sup>) when compared to no pathology (AD-LB<sup>-</sup>). *BIN1* was also not associated with the risk of  
320 AD<sup>+</sup>LB<sup>+</sup> co-pathology when compared to sole AD pathology (AD<sup>+</sup>LB<sup>-</sup>) pathology. These results further  
321 corroborate that *BIN1* is also a driver of AD pathology. In the largest previous GWAS of LB pathology,  
322 Chia *et al.* found that *BIN1* is a risk locus for pathologically confirmed LB dementia (OR = 1.25,  $P =$   
323  $4.16 \times 10^{-9}$  for rs6733839, in linkage disequilibrium with rs4663105 with  $R^2 = 0.8968$ ) [13].  
324 However, when gathering individuals, Chia *et al.* did not select against AD pathology, which was  
325 presumably far more prevalent in the LB<sup>+</sup> case group than in the control group. Given that we do not  
326 observe an association of rs4663105 with risk for AD-LB<sup>+</sup> pathology, the *BIN1* association reported  
327 in [13] may have been driven by the AD<sup>+</sup>LB<sup>+</sup> subgroup within the LB<sup>+</sup> group. However, our findings  
328 are limited by the size of our AD-LB<sup>+</sup> group (N = 158); the lower statistical power of the AD-LB<sup>+</sup>  
329 pathology versus AD-LB<sup>-</sup> pathology GWAS was likely also the reason that known synucleinopathy  
330 risk loci like *GBA* and *SNCA* did not yield genome-wide significant associations in this analysis.

331 Altogether, the current balance of evidence suggests that variants on the *BIN1* locus behave like

332 *APOE-ε4*: pathogenic *BIN1* variants increase the overall risk of LB pathology simply by increasing the  
333 risk of AD pathology (which is frequently accompanied by LB pathology), but they do not affect the  
334 risk of AD-LB<sup>+</sup> pathology or the risk of co-pathology (AD<sup>+</sup>LB<sup>+</sup>) among AD<sup>+</sup> individuals. It is worth  
335 mentioning that the effect of *BIN1* on the risk of AD pathology may be lifestyle-dependent, as we did  
336 not observe any association of *BIN1* with pathology in the subset of Rush individuals alone (**Suppl.**  
337 **Fig. 2; Suppl. Table 4**). The monastic life of these subjects likely militates against disease.  
338 Future studies should continue the effort of determining the risk loci for AD pathology, LB pathology,  
339 or AD-LB co-pathology using pathologically well-categorized and clinically unbiased cohorts. It may  
340 be worth focusing on comparing AD<sup>+</sup>LB<sup>+</sup> to AD<sup>+</sup>LB<sup>-</sup> groups to identify LB pathology risk loci because  
341 the sample size of either phenotype is larger than AD-LB<sup>+</sup>. Further study of the AD<sup>+</sup>LB<sup>+</sup> versus AD<sup>+</sup>LB<sup>-</sup>  
342 and AD-LB<sup>+</sup> versus AD-LB<sup>-</sup> contrasts may also reveal possible differences between genetic risk factors  
343 underlying LB pathology in the presence or absence of AD pathology; we propose a hypothetical  
344 genetic model in **Suppl. Fig. 3**.

345

#### 346 **Conclusion**

347 In conclusion, our set of GWAS meta-analyses indicates that while *APOE-ε4* is a risk factor for AD  
348 pathology and increases risk of AD-LB co-pathology, it is not a risk factor for LB pathology  
349 independent of AD pathology or along with AD pathology. This is also true of variants on the *BIN1*  
350 locus; therefore, neither *APOE-ε4* nor *BIN1* variants appear to play a specific mechanistic role in the  
351 emergence of LB pathology. We provide GWAS meta-analysis summary statistics that will enable  
352 more reliable, pathologically precise polygenic risk score calculations for AD, LB dementia, and  
353 related disorders. Ultimately, we shed light on the genetic bases of AD and LB pathology, which will  
354 be useful for further unraveling the etiology of these debilitating pathologies and developing accurate  
355 and effective interventions.

356 **Acknowledgments**

357 This research is based on data collected by the National Alzheimer’s Coordinating Center and the  
358 Rush University Medical Center.

359

360 **Funding**

361 This work was supported by the National Institute on Aging grants 1R01-AG060747 (MDG) and  
362 K99AG075238 (MEB), the European Union’s Horizon 2020 Research and Innovation Program under  
363 the Marie Skłodowska-Curie Actions grant 890650 (YLG), and the Alzheimer’s Association grant  
364 AARF-20-683984 (MEB).

365

366 **Availability of data and materials**

367 The summary statistics from our genome-wide association study meta-analyses are available online  
368 (URL to NIAGADS and EBI GWAS catalogue to be updated at publication).

369

370 **Authors’ contributions**

371 Concept and design: YLG, MDG. Data analysis: ST and YLG. Drafting of the manuscript: ST, YLG, NK,  
372 MDG. Critical review of the manuscript: ST, YLG, NK, MEB, and MDG. Funding acquisition: YLG, MEB,  
373 and MDG.

374

375 **Declarations**

376 **Competing interests**

377 The authors declare that they have no competing interests.

378

379 **Ethical approval and consent to participate**

380 Participants or their caregivers provided written informed consent in the original studies. The  
381 current study protocol was granted an exemption by the Stanford University institutional review  
382 board because the analyses were carried out on deidentified data; therefore, additional informed  
383 consent was not required.

384

385

386

387

388

## 389 References

- 390 1. Beach TG, Monsell SE, Phillips LE, Kukull W (2012) Accuracy of the Clinical Diagnosis of  
391 Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. *J*  
392 *Neuropathol Exp Neurol* 71:266–273. <https://doi.org/10.1097/NEN.0b013e31824b211b>
- 393 2. Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, Myers AJ et al (2014) Genome-  
394 wide association meta-analysis of neuropathologic features of Alzheimer's disease and  
395 related dementias. *PLoS Genet* 10. <https://doi.org/10.1371/journal.pgen.1004606>
- 396 3. Bellenguez C, Küçükali F, Jansen IE et al (2022) New insights into the genetic etiology of  
397 Alzheimer's disease and related dementias. *Nat Genet* 54:412–436.  
398 <https://doi.org/10.1038/s41588-022-01024-z>
- 399 4. Belloy ME, Napolioni V, Greicius MD (2019) A Quarter Century of APOE and Alzheimer's  
400 Disease: Progress to Date and the Path Forward. *Neuron* 101:820–838.  
401 <https://doi.org/10.1016/j.neuron.2019.01.056>
- 402 5. Berge G, Sandro SB, Ronge A et al (2014) Apolipoprotein E  $\epsilon$ 2 genotype delays onset of  
403 dementia with Lewy bodies in a Norwegian cohort. *J Neurol Neurosurg Psychiatry* 85:1227–  
404 1231. <https://doi.org/10.1136/jnnp-2013-307228>
- 405 6. Blennow K, Zetterberg H (2018) Biomarkers for Alzheimer's disease: current status and  
406 prospects for the future. *J Intern Med* 284:643–663. <https://doi.org/10.1111/joim.12816>
- 407 7. Boluda S, Toledo JB, Irwin DJ et al (2014) A comparison of A $\beta$  amyloid pathology staging  
408 systems and correlation with clinical diagnosis. *Acta Neuropathol* 128:543–550.  
409 <https://doi.org/10.1007/s00401-014-1308-9>
- 410 8. Braak H, Alafuzoff A, Arzberger T, Kretschmar H, Del Tredici K (2006) Staging of Alzheimer  
411 disease-associated neurofibrillary pathology using paraffin sections and  
412 immunocytochemistry. *Acta Neuropathol* 112:389–404. [https://doi.org/10.1007/s00401-](https://doi.org/10.1007/s00401-006-0127-z)  
413 [006-0127-z](https://doi.org/10.1007/s00401-006-0127-z)
- 414 9. Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age  
415 categories. *Neurobiol Aging* 18:351–357. [https://doi.org/10.1016/s0197-4580\(97\)00056-0](https://doi.org/10.1016/s0197-4580(97)00056-0)
- 416 10. Bras J, Guerreiro R, Darwent L, Parkkinen L, Ansorge O et al (2014) Genetic analysis  
417 implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with  
418 Lewy bodies. *Hum Mol Genet* 23:6139–6146. <https://doi.org/10.1093/hmg/ddu334>
- 419 11. Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ et al (2015) Second-  
420 generation PLINK: rising to the challenge of larger and richer datasets. *GigaScience* 4.  
421 <https://doi.org/10.1186/s13742-015-0047-8>
- 422 12. Chang D, Nalls M, Hallgrímsdóttir I et al (2017) A meta-analysis of genome-wide association  
423 studies identifies 17 new Parkinson's disease risk loci. *Nat Genet* 49:1511–1516.  
424 <https://doi.org/10.1038/ng.3955>
- 425 13. Chia R, Sabir MS, Bandres-Ciga S, Saez-Atienzar S, Reynolds RH et al (2021) Genome  
426 sequencing analysis identifies new loci associated with Lewy body dementia and provides  
427 insights into its genetic architecture. *Nat Genet* 53:294–303.  
428 <https://doi.org/10.1038/s41588-021-00785-3>


- 429 14. Chung EJ, Babulal GM, Monsell SE, Cairns NJ, Roe CM, Morris JC et al (2015) Clinical Features  
430 of Alzheimer Disease With and Without Lewy Bodies. *JAMA Neurol* 72:789–796.  
431 <https://doi.org/10.1001/jamaneurol.2015.0606>
- 432 15. Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M et al (2010) Association of CR1, CLU  
433 and PICALM with Alzheimer’s disease in a cohort of clinically characterized and  
434 neuropathologically verified individuals. *Hum Mol Genet* 19:3295–3301.  
435 <https://doi.org/10.1093/hmg/ddq221>
- 436 16. Davis AA et al (2020) APOE genotype regulates pathology and disease progression in  
437 synucleinopathy. *Sci Transl Med* 12. <https://doi.org/10.1126/scitranslmed.aay3069>
- 438 17. DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer’s disease. *Mol*  
439 *Neurodegeneration* 14. <https://doi.org/10.1186/s13024-019-0333-5>
- 440 18. Dickson DW, Heckman MG, Murray ME, Soto AI, Walton RL et al (2018) APOE  $\epsilon$ 4 is associated  
441 with severity of Lewy body pathology independent of Alzheimer pathology. *Neurology*  
442 91:1182–1195. <https://doi.org/10.1212%2FWNL.00000000000006212>
- 443 19. Escott-Price V, Hardy J (2022) Genome-wide association studies for Alzheimer’s disease:  
444 bigger is not always better. *Brain Commun* 4:125.  
445 <https://doi.org/10.1093/braincomms/fcac125>
- 446 20. Escott-Price V, Myers AJ, Huentelman M, Hardy J (2017) Polygenic Risk Score Analysis of  
447 Pathologically Confirmed Alzheimer Disease. *Ann Neurol* 82:311–314.  
448 <https://doi.org/10.1002/ana.24999>
- 449 21. Ferman TJ, Boeve BF, Smith GE, Lin SC, Silber MH et al (2011) Inclusion of RBD improves the  
450 diagnostic classification of dementia with Lewy bodies. *Neurology* 77:875–882.  
451 <https://doi.org/10.1212/WNL.0b013e31822c9148>
- 452 22. Fyfe I (2020) APOE\* $\epsilon$ 4 promotes synucleinopathy. *Nat Rev Neurol* 16.  
453 <https://doi.org/10.1038/s41582-020-0335-5>
- 454 23. Goldberg TE, Huey ED, Devanand DP (2020) Association of APOE e2 genotype with  
455 Alzheimer’s and non-Alzheimer’s neurodegenerative pathologies. *Nat Commun* 11.  
456 <https://doi.org/10.1038/s41467-020-18198-x>
- 457 24. Guerreiro R, Ross OA, Kun-Rodrigues C, Hernandez DG, Orme T et al (2018) Investigating the  
458 genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association  
459 study. *Lancet Neurol* 17:64–74. [https://doi.org/10.1016/s1474-4422\(17\)30400-3](https://doi.org/10.1016/s1474-4422(17)30400-3)
- 460 25. Hohl U, Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J (2000) Diagnostic Accuracy of  
461 Dementia With Lewy Bodies. *Arch Neurol* 57:347–351.  
462 <https://doi.org/10.1001/archneur.57.3.347>
- 463 26. Hunter JD (2007) Matplotlib: A 2D graphics environment. *J Comput Inf Sci Eng* 9:90–95.  
464 <https://doi.org/10.1109/MCSE.2007.55>
- 465 27. Kaivola K et al (2023) Genome-wide structural variant analysis identifies risk loci for non-  
466 Alzheimer’s dementias. *Cell Genom* 3. <https://doi.org/10.1016/j.xgen.2023.100316>
- 467 28. Kaivola K, Shah Z, Chia R, International LBD Genomics Consortium, Scholz S (2022) Genetic  
468 evaluation of dementia with Lewy bodies implicates distinct disease subgroups. *Brain*  
469 145:1757–1762. <https://doi.org/10.1093/brain/awab402>



- 470 29. Karczewski KJ, Francioli LC, Tiao G et al (2020) The mutational constraint spectrum  
471 quantified from variation in 141,456 humans. *Nature* 581:434–443.  
472 <https://doi.org/10.1038/s41586-020-2308-7>
- 473 30. Kotzbauer PT, Trojanowski JQ, Lee VMY (2001) Lewy body pathology in Alzheimer's disease.  
474 *J Mol Neurosci* 17:225–232. <https://doi.org/10.1385/JMN:17:2:225>
- 475 31. Koutsodendris N, Nelson MR, Rao A, Huang Y (2022) Apolipoprotein E and Alzheimer's  
476 Disease: Findings, Hypotheses, and Potential Mechanisms. *Annu Rev Path* 17:73–99.  
477 <https://doi.org/10.1146/annurev-pathmechdis-030421-112756>
- 478 32. Lantero Rodriguez J, Karikari TK, Suárez-Calvet M et al (2020) Plasma p-tau181 accurately  
479 predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves  
480 the clinical characterisation of cognitive decline. *Acta Neuropathol* 140:267–278.  
481 <https://doi.org/10.1007/s00401-020-02195-x>
- 482 33. Le Guen Y, Belloy ME, Napolioni V et al (2021) A novel age-informed approach for genetic  
483 association analysis in Alzheimer's disease. *Alzheimer's Res Therapy* 13.  
484 <https://doi.org/10.1186/s13195-021-00808-5>
- 485 34. Leverenz JB, Fishel MA, Peskind ER et al (2006) Lewy Body Pathology in Familial Alzheimer  
486 Disease: Evidence for Disease- and Mutation-Specific Pathologic Phenotype. *Arch Neurol*  
487 63:370–376. <https://doi.org/10.1001/archneur.63.3.370>
- 488 35. Machiela MJ, Chanock SJ (2015) LDlink: a web-based application for exploring population-  
489 specific haplotype structure and linking correlated alleles of possible functional variants.  
490 *Bioinformatics* 31:3555–3557. <https://doi.org/10.1093/bioinformatics/btv402>
- 491 36. Majbour N, Aasly J, Abdi I, Ghanem S, Erskine D, van de Berg W, El-Agnaf O (2022) Disease-  
492 associated  $\alpha$ -synuclein aggregates as biomarkers of Parkinson disease clinical stage.  
493 *Neurology* 99. <https://doi.org/10.1212/WNL.0000000000201199>
- 494 37. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM (2010) Robust relationship  
495 inference in genome-wide association studies. *Bioinformatics* 26:2867–2873.  
496 <https://doi.org/10.1093/bioinformatics/btq559>
- 497 38. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J et al (2017) Diagnosis and  
498 management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.  
499 *Neurology* 89:88–100. <https://doi.org/10.1212/WNL.0000000000004058>
- 500 39. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ et al (1991) The Consortium to Establish a  
501 Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic  
502 assessment of Alzheimer's disease. *Neurology* 41:479–486.  
503 <https://doi.org/10.1212/wnl.41.4.479>
- 504 40. Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S et al (2019) Identification  
505 of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis  
506 of genome-wide association studies. *Lancet Neurol* 18:1091–1102.  
507 [https://doi.org/10.1016%2FS1474-4422\(19\)30320-5](https://doi.org/10.1016%2FS1474-4422(19)30320-5)
- 508 41. Nelson PT, Alazufoff I, Bigio EH, Bouras C, Braak H et al (2012) Correlation of Alzheimer  
509 Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. *J*  
510 *Neuropathol Exp Neurol* 71:362–381. <https://doi.org/10.1097/nen.0b013e31825018f7>


- 511 42. Pillai JA, Bena J, Bonner-Jackson A, Leverenz JB (2021) Impact of APOE  $\epsilon$ 4 genotype on initial  
512 cognitive symptoms differs for Alzheimer's and Lewy body neuropathology. *Alzheimer's Res*  
513 *Therapy* 13. <https://doi.org/10.1186/s13195-021-00771-1>
- 514 43. Poggiolini I, Gupta V, Lawton M, Lee S, El-Turabi A et al (2022) Diagnostic value of  
515 cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. *Brain* 145:584–  
516 595. <https://doi.org/10.1093/brain/awab431>
- 517 44. Rahimi J, Kovacs GG (2014) Prevalence of mixed pathologies in the aging brain. *Alzheimer's*  
518 *Res Therapy* 6. <https://doi.org/10.1186/s13195-014-0082-1>
- 519 45. Rizzo G, Arcuti S, Copetti M, Alessandria M, Savica R et al (2018) Accuracy of clinical diagnosis  
520 of dementia with Lewy bodies: a systematic review and meta-analysis. *J Neurol Neurosurg*  
521 *Psychiatry* 89:358–366. <https://doi.org/10.1136/jnnp-2017-316844>
- 522 46. Robinson JL, Lee EB, Xie SX, Rennert L, Suh E et al (2018) Neurodegenerative disease  
523 concomitant proteinopathies are prevalent, age-related and APOE4-associated. *Brain*  
524 141:2181–2193. <https://doi.org/10.1093/brain/awy146>
- 525 47. Russo MJ, Orru CD, Concha-Marambio L et al (2021) High diagnostic performance of  
526 independent alpha-synuclein seed amplification assays for detection of early Parkinson's  
527 disease. *acta neuropathol commun* 9. <https://doi.org/10.1186/s40478-021-01282-8>
- 528 48. Sabir MS, Blauwendraat C, Ahmed S, Serrano GE, Beach TG et al (2019) Assessment of APOE  
529 in atypical parkinsonism syndromes. *Neurobiol Dis* 127:142–146.  
530 <https://doi.org/10.1016%2Fj.nbd.2019.02.016>
- 531 49. Savica R, Beach TG, Hentz JG et al (2019) Lewy body pathology in Alzheimer's disease: A  
532 clinicopathological prospective study. *Acta Neurol Scand* 139:76–81.  
533 <https://doi.org/10.1111/ane.13028>
- 534 50. Skogseth R, Hortobágyi T, Soennesyn H, Chwiszczuk L, Ffytche D et al (2017) Accuracy of  
535 clinical diagnosis of dementia with Lewy bodies versus neuropathology. *J Alzheimer's Dis*  
536 59:1139–1152. <https://doi.org/10.3233/jad-170274>
- 537 51. Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A $\beta$ -deposition in the human brain and  
538 its relevance for the development of AD. *Neurology* 58:1791–1800.  
539 <https://doi.org/10.1212/WNL.58.12.1791>
- 540 52. Tsuang D, Leverenz JB, Lopez OL et al (2013) APOE  $\epsilon$ 4 Increases Risk for Dementia in Pure  
541 Synucleinopathies. *JAMA Neurol* 70:223–228.  
542 <https://doi.org/10.1001/jamaneurol.2013.600>
- 543 53. Twohig D, Nielsen HM (2019)  $\alpha$ -synuclein in the pathophysiology of Alzheimer's disease. *Mol*  
544 *Neurodegeneration* 14. <https://doi.org/10.1186/s13024-019-0320-x>
- 545 54. Walker JM, Richardson TE (2023) Cognitive resistance to and resilience against multiple  
546 comorbid neurodegenerative pathologies and the impact of APOE status. *J Neuropathol Exp*  
547 *Pathol* 82:110–119. <https://doi.org/10.1093/jnen/nlac115>
- 548 55. Willer CJ, Li Y, Abecasis GR (2010) METAL: fast and efficient meta-analysis of genomewide  
549 association scans. *Bioinformatics* 26:2190–2191.  
550 <https://doi.org/10.1093/bioinformatics/btq340>

- 551            56. Yin L, Zhang H, Tang Z, Xu J, Yin D et al (2021) rMVP: A Memory-efficient, Visualization-  
552            enhanced, and Parallel-accelerated Tool for Genome-wide Association Study. Genomics  
553            Proteomics Bioinformatics 19:619–628. <https://doi.org/10.1016/j.gpb.2020.10.007>  
554            57. Zhao N et al (2020) APOE4 exacerbates alpha-synuclein pathology and related toxicity  
555            independent of amyloid. Sci Transl Med 12. <https://doi.org/10.1126/scitranslmed.aay1809>



556  
557  
558  
559

**Figure 1. Schemes used to classify individuals. a.** Criteria from Tsuang *et al.* (2013) [52]. **b.** Criteria from Kaivola *et al.* (2022) [28]. **c.** Criteria in the present study.



560  
561 **Figure 2. Manhattan plots of genetic association with pathology contrasts. a.** Association with  
562 AD+LB+ pathology versus AD-LB- pathology. **b.** Association with AD+LB- pathology versus AD-LB-  
563 pathology. **c.** Association with AD-LB+ pathology versus AD-LB- pathology. **d.** Association with  
564 AD+LB+ pathology versus AD+LB- pathology. Variants at two novel loci exhibited genome-wide  
565 significant associations in the AD-LB+ versus AD-LB- analysis (rs112017605 on both an intron of  
566 *AC024598.1* and an intron of *AC067752.1* on chromosome 10 and rs116691607 on an intron of *BLMH*  
567 on chromosome 17) (**c**; **Suppl. Table 2**), but we do not discuss these candidates in the main text  
568 because neither was flanked by a set of nearby variants in linkage disequilibrium, raising concern  
569 that these could be spurious signals.

570 **Table 1 Demographics from participants included in the current study, pathologically**  
 571 **evaluated in the National Alzheimer’s Coordinating Center (NACC) or Rush University Medical**  
 572 **Center databases.** AD+LB+ corresponds to AD-LB co-pathology individuals, AD+LB- corresponds to  
 573 sole AD pathology individuals, AD-LB+ corresponds to sole LB pathology individuals, and AD-LB-  
 574 corresponds to individuals with neither pathology. AAD is age-at-death, reported as mean ± standard  
 575 deviation.  
 576

	Overall			NACC			Rush		
	N	N female	AAD	N	N female	AAD	N	N female	AAD
<b>AD+LB+</b>	1,072	544 (51%)	82.9 ± 9.3	851	395 (46%)	80.8 ± 8.9	221	149 (67%)	91.0 ± 5.8
<b>AD+LB-</b>	2,492	1,435 (58%)	83.5 ± 9.4	1,973	1,055 (53%)	81.5 ± 9.2	519	380 (73%)	91.1 ± 5.7
<b>AD-LB+</b>	158	76 (48%)	86.6 ± 8.1	84	34 (40%)	85.4 ± 8.9	74	42 (57%)	88.0 ± 6.8
<b>AD-LB-</b>	1,263	706 (56%)	87.3 ± 8.1	724	376 (52%)	86.8 ± 8.8	539	330 (61%)	87.9 ± 7.1

577

578 **Table 2. *APOE-ε4* allele frequency by pathology category.** The second and third columns indicate  
579 the frequency of *APOE-ε4* among the NACC or Rush individuals in each category. Frequencies are  
580 reported as count of *APOE-ε4* alleles out of total allele count.  
581

	Overall	NACC	Rush
<b>AD+LB+</b>	744/2,144 (34.7%)	662/1,702 (38.9%)	82/442 (18.6%)
<b>AD+LB-</b>	1,685/4,984 (33.8%)	1,492/3,946 (37.8%)	193/1,038 (18.6%)
<b>AD-LB+</b>	28/316 (8.9%)	20/168 (11.9%)	8/148 (5.4%)
<b>AD-LB-</b>	249/2,526 (9.9%)	166/1,448 (11.5%)	83/1,078 (7.7%)

582

583 **Table 3. Number of individuals in pathology categories across analyses.** Not all classifications  
 584 were necessarily pathologically confirmed (**Suppl. Table 1**). First column: our study cohort. Next  
 585 two columns: our preliminary cohort (before the removal of individuals not classified by our criteria)  
 586 classified using literature criteria (**Fig. 1a–b**) [52, 28]. Remaining columns: category sizes in  
 587 literature cohorts [52, 28, 13, 2, 10, 14, 18, 24, 46, 48]. For Beecham *et al.*, Robinson *et al.*, and Sabir  
 588 *et al.*, only analyses of *APOE-ε4*-associated risk for LB pathology or dementia are considered [2, 46,  
 589 48]. For Guerreiro *et al.*, we describe the larger discovery cohort [24].  
 590

	Current sample	Initial sample × Tsuang <i>et al.</i> (2013) criteria	Initial sample × Kaivola <i>et al.</i> (2022) criteria	Tsuang <i>et al.</i> (2013)	Kaivola <i>et al.</i> (2022)	Chia <i>et al.</i> (2021)
AD+LB+	1,072	916	695	224	66/341 <sup>a</sup>	?
AD+LB-	2,492	2,492	3,493	244	0	0
AD-LB+	158	316	158	91	88	?
AD-LB-	1,263	1,358	908	269	2,928	4,027
LB+ <sup>b</sup>	N/A	N/A	N/A	N/A	N/A	2,591
LB- <sup>b</sup>	N/A	N/A	N/A	N/A	N/A	N/A

591

	Beecham <i>et al.</i> (2014)	Bras <i>et al.</i> (2014)	Chung <i>et al.</i> (2015)	Dickson <i>et al.</i> (2018)	Guerreiro <i>et al.</i> (2018)	Robinson <i>et al.</i> (2018)	Sabir <i>et al.</i> (2019)
AD+LB+	?	?	215	10/27/115/19/ 111/209 <sup>a</sup>	?	130/96 <sup>a,c</sup>	?
AD+LB-	?	0	316	0	0	16/60 <sup>a</sup>	0
AD-LB+	?	?	0	46/80/33 <sup>a</sup>	?	10/12/22 <sup>a</sup>	?
AD-LB-	?	2,624	0	660	3,791	0	591
LB+ <sup>b</sup>	2,391	667	N/A	N/A	1,216	N/A	525
LB- <sup>b</sup>	1,135	N/A	N/A	N/A	N/A	N/A	N/A

592

593 <sup>a</sup>In Dickson *et al.*, the AD+LB+ individuals were subdivided into individuals with moderate or high  
 594 AD pathology and brainstem, transitional, or diffuse LB pathology; the subgroup sizes are listed  
 595 in the order moderate-brainstem, moderate-transitional, *et cetera* [18]. In Robinson *et al.*, the  
 596 AD+LB+ individuals were subdivided into individuals with primary intermediate or high AD  
 597 pathology and secondary LB pathology and individuals with primary brainstem, limbic, or  
 598 neocortical LB pathology [46]. In Kaivola *et al.*, the AD+LB+ individuals were subdivided into  
 599 individuals with intermediate or high AD pathology [28]. A separate analysis was performed on  
 600 each subgroup in each of these three studies. <sup>b</sup>These rows are populated only if an analysis was  
 601 performed on an LB- or LB+ group. In this case the sizes of the corresponding subgroups are



602 marked as unknown (*e.g.*, AD+LB<sup>+</sup> and AD-LB<sup>+</sup> if LB<sup>+</sup> is known). <sup>c</sup>The six subgroups of this  
603 category were consolidated into two subgroups analyzed separately for association of *APOE-ε4*  
604 with AD co-pathology versus sole intermediate or high AD pathology or LB co-pathology versus  
605 sole brainstem, limbic, or neocortical LB pathology: 130 individuals with primary AD pathology  
606 and secondary LB pathology and 96 with primary LB pathology and secondary AD pathology,  
607 respectively [46].

608 **Table 4. Association of *APOE-ε4* (rs429358) with different pathology contrasts.** The first  
 609 column corresponds to the current study, while the following two columns correspond to results  
 610 obtained using the current sample using literature criteria to classify participants into pathology  
 611 groups (**Fig. 1a-b**) [52, 28]. The other columns correspond to results reported in the literature [52,  
 612 28, 13, 2, 10, 14, 18, 24, 46, 48]. Effect sizes are reported as OR with 95% confidence interval [CI] and  
 613 significance (*P*-value).  
 614

	Current sample	Initial sample × Tsuang <i>et al.</i> (2013) criteria	Initial sample × Kaivola <i>et al.</i> (2022) criteria	Reported by Tsuang <i>et al.</i> (2013)	Reported by Kaivola <i>et al.</i> (2022)	Reported by Chia <i>et al.</i> (2021)
<b>AD+LB+ vs. AD-LB-</b>	4.24 [3.52 5.10] (1.49e-52)	3.86 [3.23 4.63] (5.10e-49)	5.02 [3.97 6.35] (2.21e-41)	12.6 [8.1 19.8] (2.1e-28)	2.31 [1.40 3.83] (1.1e-03) 4.25 [3.35 4.39] (1.29e-32)	N/A
<b>AD+LB- vs. AD-LB-</b>	4.22 [3.60 4.96] (1.41e-69)	3.55 [3.07 4.12] (3.27e-64)	4.66 [3.87 5.60] (3.90e-60)	9.9 [6.4 15.3] (1.2e-24)	N/A	N/A
<b>AD-LB+ vs. AD-LB-</b>	0.93 [0.60 1.43] (7.34e-01)	1.46 [1.12 1.90] (5.47e-03)	1.17 [0.74 1.84] (4.95e-01)	6.1 [3.5 10.5] (1.3e-10)	0.75 [0.43 1.30] (3.1e-01)	N/A
<b>AD+LB+ vs. AD+LB-</b>	1.01 [0.90 1.13] (8.33e-01)	1.09 [0.97 1.22] (1.66e-01)	1.00 [0.88 1.14] (9.93e-01)	N/A	N/A	N/A
<b>LB+ vs. AD-LB-</b>	N/A	N/A	N/A	N/A	N/A	2.45 [2.22 2.74] (4.65e-63)
<b>LB+ vs. LB-</b>	N/A	N/A	N/A	N/A	N/A	N/A
<b>LB+ vs. AD-LB+</b>	N/A	N/A	N/A	N/A	N/A	N/A
<b>AD+ vs. AD+LB-</b>	N/A	N/A	N/A	N/A	N/A	N/A

615

616

	Reported by Beecham <i>et al.</i> (2015)	Reported by Bras <i>et al.</i> (2014) (at rs769449) <sup>b</sup>	Reported by Chung <i>et al.</i> (2015)	Reported by Dickson <i>et al.</i> (2018)	Reported by Guerreiro <i>et al.</i> (2018)	Reported by Robinson <i>et al.</i> (2018)	Reported by Sabir <i>et al.</i> (2019)
				1.88 [0.37 9.49] (4.5e-01)			
				3.42 [1.48 7.92] (4e-03)			
AD+LB+ vs. AD-LB-	N/A	N/A	N/A	3.74 [2.34 5.97] (4e-08)	N/A	N/A	N/A
				9.37 [2.90 30.24] (2e-04)			
				5.58 [3.38 9.20] (2e-11)			
AD+LB- vs. AD-LB-	N/A	N/A	N/A	6.96 [4.70 10.29] (3e-22)	N/A	N/A	N/A
				0.30 [0.10 0.87] (2.7e-02)			
AD-LB+ vs. AD-LB-	N/A	N/A	N/A	0.73 [0.40 1.34] (0.31)	N/A	N/A	N/A
				3.46 [1.66 7.22] (1e-03)			
AD+LB+ vs. AD+LB-	N/A	N/A	(3e-02)	N/A	N/A	N/A	N/A
LB+ vs. AD-LB-	N/A	2.711 [2.313 3.177] (7.09e-35)	N/A	N/A	2.40 [2.14 2.70] (1.05e-48)	N/A	2.94 [2.34 3.71] (6.6e-20)
LB+ vs. LB-	1.63 [1.52 1.76] (2.8e-11)	N/A	N/A	N/A	N/A	N/A	N/A
						2.25 [0.25 19.90] (4.66e-01)	
LB+ vs. AD-LB+	N/A	N/A	N/A	N/A	N/A	8.69 [0.70 107.39] (9.2e-01)	N/A
						9.32 [2.12 40.95] (3e-03)	
AD+ vs. AD+LB-	N/A	N/A	N/A	N/A	N/A	0.71 [0.17 2.95] (6.4e-01)	N/A
						0.93 [0.48 1.82] (8.3e-01)	

617 <sup>a</sup>In Kaivola *et al.*, Dickson *et al.*, and Robinson *et al.*, analyses were performed on separate  
618 subgroups [28, 18, 46]. The order of the results is the same as the order in which the  
619 corresponding subgroups were listed in **Suppl. Table 1**. <sup>b</sup>*APOE-ε4* and rs769449 reported in [13]  
620 and [10] are in linkage disequilibrium ( $R^2 = 0.766$ ).

621 **Table 5. Association of rs4663105 on the *BIN1* locus with different pathology contrasts.** The  
 622 first column corresponds to the current study, while the following two columns correspond to results  
 623 obtained using the current sample using literature criteria to classify participants into pathology  
 624 groups (**Fig. 1a–b**) [52, 28]. The last column corresponds to a result reported in the literature [13].  
 625 Effect sizes are reported as OR with 95% confidence interval [CI] and significance (*P*-value).  
 626

	Current study	Initial sample × Tsuang <i>et al.</i> (2013) criteria	Initial sample × Kaivola <i>et al.</i> (2022) criteria	Reported by Chia <i>et al.</i> (2021) (at rs6733839) <sup>a</sup>
AD+LB <sup>+</sup> vs. AD-LB <sup>-</sup>	1.53 [1.35 1.75] (1.35e-10)	1.55 [1.35 1.77] (2.19e-10)	1.56 [1.33 1.82] (1.99e-08)	N/A
AD+LB <sup>-</sup> vs. AD-LB <sup>-</sup>	1.40 [1.26 1.56] (6.51e-10)	1.36 [1.23 1.51] (4.45e-09)	1.36 [1.22 1.52] (6.32e-08)	N/A
AD-LB <sup>+</sup> vs. AD-LB <sup>-</sup>	1.10 [0.85 1.41] (4.76e-01)	1.20 [1.00 1.44] (4.81e-02)	1.11 [0.86 1.43] (4.18e-01)	N/A
AD+LB <sup>+</sup> vs. AD+LB <sup>-</sup>	1.13 [1.02 1.25] (1.91e-02)	1.14 [1.03 1.28] (1.57e-02)	1.20 [1.07 1.35] (2.10e-03)	N/A
LB <sup>+</sup> vs. AD-LB <sup>-</sup>	N/A	N/A	N/A	1.25 [1.16 1.35] (4.16e-09)

627 <sup>a</sup>rs4663105 and rs6733839 reported in [13] are in linkage disequilibrium ( $R^2 = 0.8968$ ).

628 **Table 6. Known Alzheimer’s disease risk loci reported in Bellenguez *et al.* (2022) and known**  
 629 **Parkinson’s disease risk loci reported in Chang *et al.* (2017) and Nalls *et al.* (2019) which are**  
 630 **associated with the corresponding pathology contrasts at the nominal significance level ( $P <$**   
 631 **0.05) [3, 12, 40]. For AD risk loci, associations with AD<sup>+</sup>LB<sup>+</sup> vs. AD<sup>-</sup>LB<sup>-</sup> or AD<sup>+</sup>LB<sup>-</sup> vs. AD<sup>-</sup>LB<sup>-</sup> are**  
 632 **shown. For PD risk loci, associations with AD<sup>+</sup>LB<sup>+</sup> vs. AD<sup>-</sup>LB<sup>-</sup>, AD<sup>-</sup>LB<sup>+</sup> vs. AD<sup>-</sup>LB<sup>-</sup>, or AD<sup>+</sup>LB<sup>+</sup> vs. AD<sup>+</sup>LB<sup>-</sup>**  
 633 **are shown. Chr:Pos:Minor:Major is chromosome, position (genome build hg38, GRCh38), and minor**  
 634 **allele and major allele in our study. Lit. effect is the effect size reported in the literature. MAF is the**  
 635 **minor allele frequency in our study. Loci with results discordant in terms of direction of effect are**  
 636 **colored orange.**  
 637

Variant	Chr:Pos:Minor:Major	Locus	Lit. effect	Study	MAF	GWAS	Effect
rs35749011	1:155162560:A:G	<i>GBA</i>	1.72 [1.59 1.89] (2.59e-35)	Chang <i>et al.</i> (2017)	1.3%	AD <sup>+</sup> LB <sup>+</sup> vs. AD <sup>+</sup> LB <sup>-</sup>	1.94 [1.24 3.06] (4.04e-03)
rs679515	1:207577223:T:C	<i>CR1</i>	1.13 [1.11 1.15] (7.20e-46)	Bellenguez <i>et al.</i> (2022)	20.2%	AD <sup>+</sup> LB <sup>-</sup> vs. AD <sup>-</sup> LB <sup>-</sup>	1.19 [1.04 1.36] (9.99e-03)
rs72777026	2:9558882:G:A	<i>ADAM17</i>	1.06 [1.04 1.08] (2.70e-08)	Bellenguez <i>et al.</i> (2022)	14.2%	AD <sup>+</sup> LB <sup>+</sup> vs. AD <sup>-</sup> LB <sup>-</sup>	1.30 [1.09 1.56] (3.92e-03)
rs72777026	2:9558882:G:A	<i>ADAM17</i>	1.06 [1.04 1.08] (2.70e-08)	Bellenguez <i>et al.</i> (2022)	14.2%	AD <sup>+</sup> LB <sup>-</sup> vs. AD <sup>-</sup> LB <sup>-</sup>	1.17 [1.01 1.37] (4.19e-02)
rs6733839	2:127135234:T:C	<i>BIN1</i>	1.17 [1.16 1.19] (6.10e-118)	Bellenguez <i>et al.</i> (2022)	41.9%	AD <sup>+</sup> LB <sup>+</sup> vs. AD <sup>-</sup> LB <sup>-</sup>	1.52 [1.34 1.74] (4.60e-10)
rs6733839	2:127135234:T:C	<i>BIN1</i>	1.17 [1.16 1.19] (6.10e-118)	Bellenguez <i>et al.</i> (2022)	41.9%	AD <sup>+</sup> LB <sup>-</sup> vs. AD <sup>-</sup> LB <sup>-</sup>	1.43 [1.29 1.60] (7.49e-11)
rs353116	2:165277122:T:C	<i>SCN3A</i>	0.94 [0.92 0.96] (2.98e-08)	Chang <i>et al.</i> (2017)	38.7%	AD <sup>+</sup> LB <sup>+</sup> vs. AD <sup>-</sup> LB <sup>-</sup>	0.85 [0.74 0.96] (1.14e-02)
rs10933431	2:233117202:G:C	<i>INPP5D</i>	0.93 [0.92 0.95] (3.60e-18)	Bellenguez <i>et al.</i> (2022)	21.8%	AD <sup>+</sup> LB <sup>-</sup> vs. AD <sup>-</sup> LB <sup>-</sup>	0.79 [0.70 0.90] (3.09e-04)
rs34311866	4:958159:C:T	<i>TMEM175/ DGKQ</i>	1.23 [1.20 1.27] (1.47e-50)	Chang <i>et al.</i> (2017)	19.1%	AD <sup>-</sup> LB <sup>+</sup> vs. AD <sup>-</sup> LB <sup>-</sup>	1.33 [1.01 1.75] (4.29e-02)
rs34311866	4:958159:C:T	<i>TMEM175/ DGKQ</i>	1.23 [1.20 1.27] (1.47e-50)	Chang <i>et al.</i> (2017)	19.1%	AD <sup>+</sup> LB <sup>+</sup> vs. AD <sup>+</sup> LB <sup>-</sup>	1.22 [1.07 1.38] (2.83e-03)
rs6846529	4:11023507:C:T	<i>CLNK/ HS3ST1</i>	1.07 [1.05 1.08] (2.20e-17)	Bellenguez <i>et al.</i> (2022)	28.0%	AD <sup>+</sup> LB <sup>-</sup> vs. AD <sup>-</sup> LB <sup>-</sup>	1.15 [1.02 1.29] (2.12e-02)
rs11724635	4:15735478:C:A	<i>FAM200B/ CD38</i>	0.90 [0.88 0.92] (1.22e-19)	Chang <i>et al.</i> (2017)	45.3%	AD <sup>-</sup> LB <sup>+</sup> vs. AD <sup>-</sup> LB <sup>-</sup>	0.71 [0.55 0.92] (9.03e-03)
rs356182	4:89704960:G:A	<i>SNCA</i>	0.75 [0.74 0.77] (5.21e-123)	Chang <i>et al.</i> (2017)	34.9%	AD <sup>-</sup> LB <sup>+</sup> vs. AD <sup>-</sup> LB <sup>-</sup>	0.74 [0.57 0.97] (2.60e-02)
rs11240336 0	5:14724304:A:T	<i>ANKK1</i>	1.09 [1.06 1.12] (2.30e-09)	Bellenguez <i>et al.</i> (2022)	7.4%	AD <sup>+</sup> LB <sup>-</sup> vs. AD <sup>-</sup> LB <sup>-</sup>	1.30 [1.06 1.59] (1.13e-02)
rs62374257	5:86927378:C:T	<i>COX7C</i>	1.07 [1.05 1.09] (1.40e-15)	Bellenguez <i>et al.</i> (2022)	22.8%	AD <sup>+</sup> LB <sup>+</sup> vs. AD <sup>-</sup> LB <sup>-</sup>	1.21 [1.04 1.41] (1.63e-02)
rs62374257	5:86927378:C:T	<i>COX7C</i>	1.07 [1.05 1.09] (1.40e-15)	Bellenguez <i>et al.</i> (2022)	22.8%	AD <sup>+</sup> LB <sup>-</sup> vs. AD <sup>-</sup> LB <sup>-</sup>	1.26 [1.11 1.43] (3.83e-04)
rs6605556	6:32615322:G:A	<i>HLA</i>	0.91 [0.90 0.93] (7.10e-20)	Bellenguez <i>et al.</i> (2022)	16.0%	AD <sup>+</sup> LB <sup>+</sup> vs. AD <sup>-</sup> LB <sup>-</sup>	0.81 [0.69 0.96] (1.67e-02)

rs6605556	6:32615322:G:A	HLA	0.91 [0.90 0.93] (7.10e-20)	Bellenguez <i>et al.</i> (2022)	16.0%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	0.87 [0.76 1.00] (4.57e-02)
rs9275326	6:32698883:T:C	HLA-DRB6/ HLA-DQA1	0.85 [0.82 0.89] (1.26e-13)	Chang <i>et al.</i> (2017)	9.8%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	0.74 [0.60 0.91] (4.75e-03)
rs10947943	6:41036354:A:G	TREM2	0.94 [0.93 0.96] (1.10e-09)	Bellenguez <i>et al.</i> (2022)	14.4%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	0.86 [0.75 1.00] (4.51e-02)
rs14333248 4	6:41161469:T:C	TREM2	1.41 [1.32 1.50] (2.80e-25)	Bellenguez <i>et al.</i> (2022)	1.3%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	1.99 [1.09 3.62] (2.50e-02)
rs14333248 4	6:41161469:T:C	TREM2	1.41 [1.32 1.50] (2.80e-25)	Bellenguez <i>et al.</i> (2022)	1.3%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	1.87 [1.11 3.16] (1.97e-02)
rs785129	6:114291731:T:C	HS3ST5	1.04 [1.03 1.06] (2.40e-09)	Bellenguez <i>et al.</i> (2022)	34.7%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	1.19 [1.04 1.36] (1.25e-02)
rs13237518	7:12229967:A:C	TMEM106B	0.96 [0.94 0.97] (4.90e-11)	Bellenguez <i>et al.</i> (2022)	42.1%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	1.23 [1.08 1.39] (1.29e-03)
rs13237518	7:12229967:A:C	TMEM106B	0.96 [0.94 0.97] (4.90e-11)	Bellenguez <i>et al.</i> (2022)	42.1%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	1.12 [1.01 1.24] (3.34e-02)
rs76928645	7:54873635:T:C	SEC61G	0.93 [0.91 0.95] (1.60e-10)	Bellenguez <i>et al.</i> (2022)	10.2%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	0.81 [0.65 1.00] (4.84e-02)
rs7384878	7:100334426:C:T	ZCWPW1/ NYAP1	0.92 [0.91 0.94] (1.10e-26)	Bellenguez <i>et al.</i> (2022)	29.3%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	0.85 [0.75 0.95] (5.45e-03)
rs591323	8:16839582:A:G	MICU3	0.91 [0.89 0.94] (2.38e-11)	Chang <i>et al.</i> (2017)	27.2%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	1.18 [1.02 1.36] (2.28e-02)
rs73223431	8:27362470:T:C	PTK2B	1.07 [1.06 1.08] (4.00e-22)	Bellenguez <i>et al.</i> (2022)	36.4%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	1.16 [1.04 1.29] (6.67e-03)
rs11787077	8:27607795:T:C	CLU	0.91 [0.90 0.92] (1.70e-44)	Bellenguez <i>et al.</i> (2022)	38.5%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	0.85 [0.74 0.97] (1.33e-02)
rs11787077	8:27607795:T:C	CLU	0.91 [0.90 0.92] (1.70e-44)	Bellenguez <i>et al.</i> (2022)	38.5%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	0.89 [0.80 0.99] (3.43e-02)
rs7912495	10:11676714:G:A	ECHDC3	1.06 [1.05 1.08] (9.70e-19)	Bellenguez <i>et al.</i> (2022)	46.1%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	1.17 [1.03 1.33] (1.47e-02)
rs7912495	10:11676714:G:A	ECHDC3	1.06 [1.05 1.08] (9.70e-19)	Bellenguez <i>et al.</i> (2022)	46.1%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	1.13 [1.01 1.25] (2.56e-02)
rs3851179	11:86157598:T:C	PICALM	0.90 [0.89 0.92] (3.00e-48)	Bellenguez <i>et al.</i> (2022)	35.2%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	0.86 [0.77 0.96] (7.92e-03)
rs11218343	11:121564878:C:T	SORL1	0.84 [0.81 0.87] (1.40e-21)	Bellenguez <i>et al.</i> (2022)	3.6%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	0.72 [0.55 0.95] (2.12e-02)
rs329648	11:133895472:T:C	MIR4697	1.09 [1.07 1.12] (1.11e-13)	Chang <i>et al.</i> (2017)	35.0%	AD*LB <sup>+</sup> vs. AD*LB <sup>-</sup>	0.88 [0.79 0.99] (2.62e-02)
rs6489896	12:113281983:C:T	TPCN1	1.08 [1.05 1.10] (1.80e-09)	Bellenguez <i>et al.</i> (2022)	7.0%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	1.31 [1.01 1.69] (4.04e-02)
rs11610045	12:132487182:A:G	FBRSL1	1.06 [1.04 1.08] (1.77e-10)	Nalls <i>et al.</i> (2019)	48.2%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	0.86 [0.76 0.98] (2.03e-02)
rs12147950	14:37520065:T:C	MIPOL1	0.95 [0.93 0.97] (3.54e-08)	Nalls <i>et al.</i> (2019)	43.2%	AD-LB <sup>+</sup> vs. AD-LB <sup>-</sup>	1.29 [1.00 1.65] (4.59e-02)
rs17125924	14:52924962:G:A	FERMT2	1.10 [1.07 1.12] (8.30e-16)	Bellenguez <i>et al.</i> (2022)	9.0%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	1.27 [1.00 1.60] (4.95e-02)
rs17125924	14:52924962:G:A	FERMT2	1.10 [1.07 1.12] (8.30e-16)	Bellenguez <i>et al.</i> (2022)	9.0%	AD*LB <sup>+</sup> vs. AD-LB <sup>-</sup>	1.38 [1.14 1.67] (8.73e-04)

<b>rs11761801</b> 7	15:63277703:T:C	<i>APH1B</i>	1.11 [1.09 1.13] (2.20e-25)	Bellenguez <i>et al.</i> (2022)	13.6%	AD*LB* vs. AD-LB*	1.20 [1.03 1.40] (2.00e-02)
<b>rs1140239</b>	16:30010081:T:C	<i>DOC2A</i>	0.94 [0.93 0.96] (2.60e-13)	Bellenguez <i>et al.</i> (2022)	38.0%	AD*LB* vs. AD-LB*	0.81 [0.71 0.93] (3.17e-03)
<b>rs4784227</b>	16:52565276:T:C	<i>TOX3</i>	1.09 [1.06 1.12] (9.75e-11)	Chang <i>et al.</i> (2017)	24.7%	AD*LB* vs. AD-LB*	0.73 [0.54 0.98] (3.72e-02)
<b>rs450674</b>	16:79574511:C:T	<i>MAF</i>	0.96 [0.95 0.98] (3.20e-08)	Bellenguez <i>et al.</i> (2022)	36.8%	AD*LB* vs. AD-LB*	0.87 [0.78 0.97] (1.01e-02)
<b>rs56407236</b>	16:90103687:A:G	<i>PRDM7</i>	1.11 [1.08 1.14] (6.50e-15)	Bellenguez <i>et al.</i> (2022)	6.3%	AD*LB* vs. AD-LB*	1.38 [1.06 1.79] (1.67e-02)
<b>rs616338</b>	17:49219935:T:C	<i>ABI3</i>	1.32 [1.23 1.42] (2.80e-14)	Bellenguez <i>et al.</i> (2022)	1.1%	AD*LB* vs. AD-LB*	2.35 [1.02 5.41] (4.47e-02)
<b>rs12151021</b>	19:1050875:A:G	<i>ABCA7</i>	1.10 [1.09 1.12] (1.60e-37)	Bellenguez <i>et al.</i> (2022)	33.3%	AD*LB* vs. AD-LB*	1.23 [1.07 1.42] (3.69e-03)
<b>rs12151021</b>	19:1050875:A:G	<i>ABCA7</i>	1.10 [1.09 1.12] (1.60e-37)	Bellenguez <i>et al.</i> (2022)	33.3%	AD*LB* vs. AD-LB*	1.21 [1.08 1.35] (1.18e-03)
<b>rs9304690</b>	19:49950060:T:C	<i>SIGLEC11</i>	1.05 [1.03 1.07] (4.70e-09)	Bellenguez <i>et al.</i> (2022)	25.0%	AD*LB* vs. AD-LB*	1.19 [1.03 1.37] (1.87e-02)

638